Replies to post #507961 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

I would offer that the proven success of NWBO’s DCVax is a “news story” worthy of media coverage and appears to have been sidelined

It was covered in the previous two decades when were they near approval.

Sometimes the story gets stale.

[no2koolaid]

A large part of the reason BP spends heavily on advertising, beside the fact they can, is because, courtesy of the Clinton Administration, we have direct to consumer marketing that is not allowed in the EU (as I mentioned in a previous post). It is why smaller companies struggle to compete with marketing/advertising.

This was most obvious in one of the most insidious examples in pharma history. Purdue Pharma's marketing included supporting various doctors to push their opioids as not addictive...that is right...NOT addictive as opposed to those of others. Why? Because Purdue claimed they had an abuse deterrent mechanism that prevented dose dumping. As if an opioid was not addictive. Yet, if the FDA was paying attention, the data showed Purdue's deterrent was not as long lasting as claimed. Purdue filed Chp 7 and continues to pay fines and settlements, as do their owners (it is private). Yet, Sackett family still pocketed billions. The FDA? They drank the kool-aid.

[biosectinvestor]

The reference to me misrepresented my thoughts there. Drugs get coverage when they are no longer embargoed and get a PR of their results or get published in a major journal, also often accompanied with a PR.

Most such articles, regardless of whether the research was done by an OTC microcap or a big pharma company, get coverage is the results are notable. Those events have not yet happened here, not since the quite good coverage of the interim results that were published and then widely covered in the US and international press, particularly in the UK.